CATB Data Pushed Back To Q1, SMMT At Peak, TRIB Pounded, OTIC Hits Right Notes

Shares of Summit Therapeutics plc (SMMT) rose as much as 128% on Tuesday, following a $562 million license and collaboration agreement, it inked with Sarepta Therapeutics (SRPT).

from RTT - Biotech http://ift.tt/2dvUamL
via IFTTT